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The stimulation of cholinergic receptors in target cells during a critical developmental period
provides signals that influence cell replication and differentiation. Accordingly, environmental
agents that promote cholinergic activity evoke neurodevelopmental damage because of the
inappropriate timing or intensity of stimulation. Nicotine evokes mitotic arrest in brain cells
possessing high concentrations of nicotinic cholinergic receptors. In addition, the cholinergic
overstimulation programs the expression of genes that evoke apoptosis and delayed cell loss.
Effects of cholinesterase inhibitors exhibit many similarities to those of nicotine. Chlorpyrifos
administered to developing rats in doses that do not evoke signs of overt toxicity decreased DNA
synthesis and caused shortfalls in cell numbers in brain regions enriched in cholinergic
innervation. In embryo cultures, chlorpyrifos also evoked apoptosis during neurulation. However,
chlorpyrifos also evokes noncholinergic disruption of cell development by interfering with cell
signaling via adenylyl cyclase, leading to widespread disruption that is not limited to cholinergic
systems. We have tested this hypothesis in vitro with PC12 cells, which lack the enzymes
necessary to produce chlorpyrifos oxon, the metabolite that inhibits cholinesterase. Chlorpyrifos
inhibited DNA synthesis in undifferentiated PC12 cells, which have relatively few cholinergic
receptors. Furthermore, chlorpyrifos was more effective than nicotine and its effects were not
blocked by cholinergic antagonists. When cells were allowed to differentiate in the presence of
chlorpyrifos, cell replication was inhibited even more profoundly and cell acquisition was arrested.
At higher concentrations, chlorpyrifos also inhibited neuritic outgrowth. Thus, chlorpyrifos elicits
damage by both noncholinergic and cholinergic mechanisms extending from early stages of
neural cell replication through late stages of axonogenesis and terminal differentiation.
Accordingly, the window of developmental vulnerability to chlorpyrifos is likely to extend from the
embryonic period into postnatal life. - Environ Health Perspect 107(Suppl 1):71-80 (1999).
http.//ehpnetl.niehs.nih.gov/docs/1999/Suppl-1/71-80slotkin/abstract.html
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Neurotransmitters as
Trophic Factors
Nearly four decades ago, Buznikov (1,2)
demonstrated that neurotransmitters were
present in high concentrations during spe-
cific phases of early development in sea
urchin embryos, unrelated to their func-
tion in synaptic communication. Subse-
quently, transient expression of these
substances and their specific receptors has
been identified during ontogeny of the
mammalian nervous system, and it is now
certain that transmitters play essential
roles in the cellular and architectural
development of the brain (3,4). During
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this period, receptor stimulation uniquely
communicates with the genes that control
cell differentiation, changing the ultimate
fate of the cell (Figure 1). As these
changes are not typical for the mature
nervous system, the ontogenetic state of
the target cell is critical in determining
whether the outcome ofreceptor stimula-
tion is an effect on cell replication, differ-
entiation, growth, death (apoptosis), or
"learning," that is, determining the future
set-point for responsiveness ofthe cell. At
the same time, these multiple roles create
a wide window ofvulnerability in which
exposure of the brain to neuroactive
chemicals that elicit or block neurotrans-
mitter responses can alter development.
Thus, unlike classical teratology, in which
the first trimester offetal development is
the most sensitive target for adverse effects
ofdrugs or chemicals, brain development
is likely to be affected by exposures rang-
ing from the early embryonic stage
through adolescence (5).
This review will focus on disruption of
brain development elicited by agents
targeting cholinergic transmission. Two of
the most widespread chemical assaults on
the fetus are cholinergic: nicotine, a direct
cholinergic agonist delivered by maternal
cigarette smoking, and insecticides, which
enhance cholinergic effects through inhibi-
tion of cholinesterase, the enzyme that
hydrolyzes acetylcholine. A focus on
cholinergic mechanisms is also appropriate
given the critical role played by acetyl-
choline in brain maturation. Cholinergic
stimulation is essential for establishment of
cerebrocortical cytoarchitecture, and even
transient interference with cholinergic
input during development produces per-
manent structural and behavioral damage
(6-8). Similarly, cholinergic overstimula-
tion at an inappropriate time leads to
developmental anomalies. In the rat, the
peak ofcholinergic tone in the cortex ordi-
narily occurs during the second postnatal
week (9). Administration ofcholinergic
agonists before that time or dietary alter-
ations that evoke early onset ofcholinergic
activity result in premature cessation of
neuronal mitosis, leading to shortfalls in
cell numbers and deficient synaptic activity
(9-12). Accordingly, it is important to
explore the mechanisms underlying the
actions of cholinotoxicants and their
impact on the developing brain.
Nicotine: Prototypic
Cholinotoxicant
The largest toxic assault on fetal develop-
ment is provided by maternal cigarette
smoking, which involves approximately
one-fourth of all pregnancies in the
United States (13,14). Epidemiologic
studies have established the tragic results:
tens of thousands ofspontaneous abor-
tions and neonatal intensive care unit
admissions annually, thousands ofperina-
tal deaths and deaths from Sudden Infant
Death Syndrome (crib death), and sub-
stantially increased incidence of learning
disabilities, behavioral problems, and
attention deficit/hyperactivity disorder
(14-20). These findings do not, however,
obligate an underlying cholinotoxic mech-
anism. Cigarette smoke contains thou-
sands ofbioactive compounds, including
hydrogen cyanide and carbon monoxide.
In addition, the smoking "life style" is
associated with multiple risk factors
including poor prenatal care and low
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socioeconomic status. Accordingly, animal
models are needed to isolate the role of
nicotine from these confounding variables.
Unfortunately the design of animal
models ofnicotine exposure has not proven
simple. Injection ofnicotine into pregnant
rats does produce behavioral (21-23) and
cellular (24-26) abnormalities, but many
ofthese effects are caused by vasoconstric-
tor effects on uteroplacental circulation,
evoking episodic hypoxia (27-30).
Nicotine injections produce high peak
plasma levels ofdrug, inducing obvious
ischemic episodes (blanching, cyanosis)
with each dose (10,31). Accordingly, in the
mid-1980s, we developed the first animal
model offetal nicotine exposure to make
use of continuous infusions delivered by
implantable osmotic minipumps (9,26,
31-34), a delivery route that avoids
hypoxia-ischemia, and that delivers a fixed
dose ofdrug simulating the steady-state
plasma levels seen in smokers or users of
transdermal nicotine patches (35,36).
Pharmacokinetic and pharmacodynamic
differences dictate the use ofhigher overall
doses in rats than in humans, so that the
critical end point is matching the plasma
concentrations and the corresponding phar-
macologic effects (36,37). Thus, in rats,
dose rates of2 to 6 mg/kg/day are necessary
to reproduce the nicotine plasma levels
found in moderate (0.5 to 1 pack/day) to
heavy (2 packs/day) smokers.
With the infusion model, we have been
able to show definitive damage to develop-
ing rat brain by doses of nicotine that
reproduce the plasma levels found in
heavy smokers (26,31-34). Two indices
of these adverse effects are illustrated in
Figure 2. In animals exposed prenatally to
nicotine, ornithine decarboxylase activity,
a marker enzyme for cell damage, is ele-
vated during the postnatal period in both
early-developing (forebrain) and late-
developing (cerebellum) brain regions even
though nicotine exposure terminates at
birth. During the same period, deficits in
total cell number, as determined by DNA
content, worsen. Subsequently, we found
that genes associated with programmed
cell death (apoptosis) are constitutively
activated by prenatal nicotine exposure
(38,39), with effects persisting into the
period of maximal cell loss; direct mor-
phological assessment ofnicotine-exposed
embryos confirmed the presence of
numerous apoptotic cells (40). Nicotine-
induced apoptosis in the developing brain
is in direct contrast to the observation that
nicotine exerts a neuroprotective effect in
theadult brain (41,42), indudingprotection
from injury-induced apoptosis (43,44).
Just as with c-fos itself (45-47), the devel-
opmental context in which nicotine expo-
sure occurs is likely to be critical for
determining whether apoptosis is evoked
or suppressed. Indeed, cholinergic agonists
and antagonists can both elicit apoptosis
depending on whether the context involves
active or desensitized receptors (48). In the
context ofextended exposure to nicotine
during fetal development, persistent induc-
tion of c-fos clearly is associated with
enhanced cell death (31), most likely from
apoptosis (40).
We also identified a second mechanism
for cell deficits caused by nicotine expo-
sure (10): inhibition of DNA synthesis
(Figure 3). Administration ofeven a single
dose of nicotine to pregnant or neonatal
The same neurotransmitter maybe usedformultiple decisions
Figure 1. Cholinotoxicant targeting ofcell development. Abbreviations: AChE, acetylcholinesterase; CPF, chlorpyri-
fos; Nic, nicotine. During development, neurotransmitters, through their receptors and associated signaling cas-
cades, control the genes that influence differentiation. Depending on the context in which stimulation occurs, the
same neurotransmitter can promote cell replication, can elicit a switch from replication to differentiation, can pro-
mote or arrest cell growth, can evoke apoptosis, or can program the genes that determine the future responsive-
ness of the cell to external stimulation. Nicotine targets nicotinic cholinergic receptors located on target cells,
directly evoking changes in gene expression. Presynaptic nicotinic receptors that modulate release ofother neuro-
transmitters produce secondary alterations of target cell development through the actions ofthese othertransmit-
ters on their respective receptors, signaling cascades and gene expression (39). Chlorpyrifos through its active
oxon metabolite inhibits acetylcholinesterase, preventing the breakdown of acetylcholine and thus enhancing
cholinergic activity. In addition, chlorpyrifos can exhibit agonistlike properties, opening and then desensitizing
nicotinic cholinergic receptor/ion channels (81), can interactwith signaling intermediates such as G-proteins and
adenylyl cyclase(80,82,83), orcan produce oxidative damageto DNA(84,85).
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Fiure Effects of nicotine on biomarkers ofcell damage (omithine decarboxylase activity) and cell number(DNA
content), evaluated in postnatal rat brain (32). Abbreviation: ODC, omithine decarboxylase. Nicotine exposure elic-
its persistent damage (elevated omithine decarboxylase activity) and cell loss (decreased DNA) despite discontinu-
ing nicotine exposure at birth. Effects are discernible in both an early-developing region (forebrain) and
late-developing region (cerebellum). Data represent means and standard errors obtained from 8 pups in each group
ateach ageforeach determination, with ANOVA main treatment effect indicated within the panels.
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rats elicits a precipitous and persistent
(several hours long) decline in DNAsynthe-
sis, with specific targeting ofbrain regions
with the highest concentrations ofnicotinic
cholinergic receptors. The same effects are
obtained when minute amounts ofnicotine
are introduced directly into the brain,
bypassing anysystemic drugeffects (10).
Simply losing cells or preventing acqui-
sition of the correct number ofcells does
not inherently account for neurobehavioral
disruption by nicotine exposure; instead it
is necessary to demonstrate that synaptic
function is affected. Because nicotine
works through cholinergic receptors, we
first evaluated effects on cholinergic trans-
mission (9,49). Using biochemical indices
ofneuronal impulse activity, we found that
prenatal nicotine exposure blunted the
ontogenetic rise ofsynaptic activity in the
forebrain and produced persistent deficits
in the hippocampus (Figure 4). However,
adverse functional effects are not limited to
cholinergic neurotransmission. Nicotinic
receptors also play a prominent role in the
activity ofcatecholaminergic systems, and
we found that fetal nicotine treatment had
adverse effects on these synapses as well,
again with the effects appearing well after
termination of nicotine exposure. Cate-
cholaminergic function showed two phases
ofsynaptic hypoactivity, one in the imme-
diate postpartum period and another
emerging with the onset ofpuberty (33),
accompanied by behavioral anomalies
(36,50,51). In the intervening stages, even
though basal activity was within normal
limits, the reactivity of noradrenergic sys-
tems to acute nicotine challenge was
obtunded in the prenatal nicotine group
(Figure 4): doses of nicotine that evoked
norepinephrine release in brain regions of
control animals were unable to do so in
the group exposed to nicotine prenatally
(52). Thus, fetal exposure to nicotine has
lasting adverse effects on synaptic perfor-
mance, effects that may not emerge fully
until adolescence.
We also have identified numerous
adverse effects ofprenatal nicotine exposure
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on postsynaptic signaling mechanisms, all
of which are potential participants in
neurobehavioral abnormalities. These
entail lasting changes in the expression of
cell signaling intermediates (53,54),
uncoupling of receptors and second mes-
senger systems from downstream cellular
events (55,56), and alterations in the
expression ofreceptor proteins themselves
(26,53,55-57). Developmental disrup-
tion by nicotine thus occurs at numerous
loci and ranges from outright cell loss to
specific alterations of neural activity to
misprogramming of receptor signaling
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dayl Podtal PdyOa1l Figure 4. Synaptic hypoactivity elicited by prenatal nicotine exposure. (A) In the forebrain, the ratio of choline
uptake to choline acetyltransferase activity (a biochemical marker of impulse activity in cholinergic projections)
Figure 3. Inhibition of DNA synthesis in rat brain shows a naturallyoccurring peak atpostnatal day 10; nicotine blunts activity before and during the developmental
regions after a single dose of nicotine (10,31,106). spike (9). (B) In the hippocampus, [3H]hemicholinium-3 binding to the high-affinity choline transporter, which is
Measurements ofPHithymidine incorporation into DNA regulated by nerve impulse activity, shows both initial postnatal deficits and a later-emerging, permanent deficit in
were made in the first30 min after nicotine administra- the nicotine group (49). (C) Noradrenergic hypoactivity is also elicited by prenatal nicotine exposure.
tion. Susceptibility is directly related to the concentra- Norepinephrine content and turnover are suppressed in the forebrain during both the initial postnatal period, and
tion of nicotinic cholinergic receptors in each region, more persistently with the onset of puberty (33). (D) Before the reemergence of deficits in the measures of basal
namely brainstem > forebrain > cerebellum. Data rep- activity, the nicotine group shows a subnormal responsiveness to acute challenges. A single injection of nicotine,
resent means and standard errors obtained from 1B--30 which releases norepinephrine in the control group, fails to do so in the nicotine group (52). Data represent means
rats at each age in each treatment group. ANOVA and standard errors obtained from 7-10 animals in each group at each age, for each type of determination.
across all ages and regions is shown within the panel; ANOVA is shown within the panels and asterisks (*) denote individual ages at which the nicotine group differs
asterisks (*) denote values that differ significantly from from the corresponding control. Individual tests were not run for acute norepinephrine release because of the
the corresponding control. absence of asignificant interaction oftreatment xregion.
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mechanisms. In trying to determine
whether these various outcomes all reflect
a similar underlying basic mechanism,
two interrelated questions emerge. First,
are the effects present at doses cor-
responding to moderate smoking (one-
half pack to one pack per day), where
growth impairment, which can lead to
nonspecific alterations, is absent? If so,
this would imply a specific mechanism
targeting the developing brain rather than
effects secondary to a more general fetal
insult. Selectivity for the developing brain
would then raise the second question: Is
stimulation ofnicotinic cholinergic recep-
tors the underlying target for the effects?
The first question can be answered defini-
tively. Lowering the dose of nicotine in
rats to the point at which growth impair-
ment vanishes and plasma levels match
those of moderate smokers still produces
all the signs of fetal brain damage that
were seen at higher doses (34,39): ele-
vated ornithine decarboxylase activity,
progressive cell loss, and deficits ofsynap-
tic activity (Figure 5). These results are
opposite from nonspecific insult, where
brain development typically is spared rela-
tive to all other growth components
(58-60). The most likely explanation for
the exquisite sensitivity of the developing
brain to nicotine-induced damage is the
targeting of specific proteins, namely
nicotinic cholinergic receptors, that have
the ability to respond to nicotine at
extremely low (nanomolar) concentrations
(26,61-63). Nicotinic receptors originate
.,Body and.tissue weights
in the fetal brain during neurulb
rise dramatically in late gestation
birth (26,62-65). We have bee
show that these receptors are
stimulated by fetal nicotine exp
evidenced by receptor upregulati
even at doses that do not impai
(34). Specific tests ofeach comf
fetal brain cell loss evoked by
have verified the involvement of
receptors, whether for inhibition
synthesis (10), stimulation of
markers (66), or promotion of
(38,67). Delayed functional sequ
as late-appearing reductions in
activity are more problematic b
the long temporal separation
initial injury and measurabl
quences. However, just as for i
immediate markers of cell dan
dose threshold for delayed neur
also lies far below that ofgrowti
ment, whether assessed bioch
(34,52) or behaviorally (50,51
By implication, the delayed el
most likely linked to the initial
mediated changes in cell deve
originating during and immedia
fetal nicotine exposure.
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Figure 5. Nicotine damages the developing brain at doses that do not compromise growth
Abbreviation: ODC, ornithine decarboxylase. Administration of 2 mg/kg/day to pregnant rats, whic
plasma levels of nicotine found in moderate smokers, results in normal body and brain region weight
spring. Nevertheless, cell damage (elevated ODC activity), cell loss(reduced DNA content) andsynaptii
ity (subnormal norepinephrine turnover) are still fully evident. Data represent means and standard em
from 5-10 animals in each group at each age for each type of determination. Differences for weights
nificant (ANOVA), but effects on biomarkers are (main treatment effect, p<0.0001 across all threebior
for each biomarkertaken individually).
ation and neurotransmitter systems including
and after acetylcholine, catecholamines (norepineph-
n able to rine, dopamine), and excitatory amino
tonically acids, which are themselves potentially
osure, as neurotoxic. Evoked release ofother trans-
ion (26), mitters that alone exert neurotrophic con-
ir growth trol of their own targets thus is likely to
ponent of produce disruption in all the sites "down-
nicotine stream' from nicotinic receptor activation.
nicotinic One issue for further consideration is
of DNA whether a specific receptor subtype is
f damage involved in nicotinic cholinergic neu-
apoptosis rotrophic actions, and by implication,
ielae such mediating the disruptive effects ofprenatal
synaptic nicotine exposure. Indeed, based on in
ecause of vitro studies, specific roles have been pos-
between tulated for control of synaptogenesis by
e conse- nicotinic receptor subtypes containing the
the more a7 subunit and for adverse effects ofnico-
nage, the tine (71). It is also apparent that develop-
ral effects ing neurons show distinct ontogenetic
h impair- profiles for expression of the genes encod-
emically ing the individual subunits of nicotinic
,68-70). receptors (72,73). Nevertheless, some key
ffects are elements are missing in the current under-
receptor- standing ofthe role ofreceptor subtypes in
:lopment the developmental effects of nicotine, as
Ltely after nearly all studies ofsubtypes in vivo have
been conducted at the level ofmRNA but
ptors can not receptor protein. Accordingly, it is
re of the unclear as to which subtypes are actually
zic activity expressed at the cell surface and whether
osure. As specific subtypes are linked differentially
eptors are to neurotrophic stimuli. Nevertheless, this
sites but absence ofknowledge concerning receptor
it at the subtypes does not obviate the clear-cut
variety of effects ofnicotine on cell development and
the linkage of these effects to nicotinic
cholinergic receptors.
Our findings indicate conclusively that
nicotine is a neuroteratogen, evoking cell
damage and reducing cell numbers,
impairing synaptic activity and behavioral
performance, and eliciting these changes at
doses commensurate with moderate smok-
ing, below the level at which fetal growth
is impaired. The underlying mechanisms
are receptor mediated, accounting for
selective effects on the brain at low-dose
thresholds and for the involvement of
brain regions and transmitter systems that
have prominent cholinergic inputs.
Receptor stimulation leads to two distinct
errors in the program ofcell development,
.hsimulates a premature change from cell replication
s in the off- to differentiation, and after a delay, initia-
ichypoactiv- tion of the program for cell damage and irs obtained apoptosis. The next issue, then, is whether
are not sig- other potential cholinotoxicants, especially
markers and insecticides, share the same mechanisms
and outcomes.
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Developmental Neurotoxicity
of Chlorpyrifos in Vivo
Increasing use is being made of the long-
lasting organophosphorus insecticide chlor-
pyrifos, largely because this agent does not
elicit organophosphate pesticide-induced
persistent neuropathies until the dose is
raised above the threshold for lethality
(74). Nevertheless, recent concern has
arisen over domestic application, which
can lead to infant exposures well above
acceptable levels (75,76). Animal studies
indicate that immature animals are far
more susceptible to acute toxicity ofchlor-
pyrifos (77-79) despite the fact that they
recover from cholinesterase inhibition
more quickly than adults (78-80). As with
other organophosphate insecticides, chlor-
pyrifos, via its reactive metabolite, chlor-
pyrifos oxon, inhibits cholinesterase and
prevents the breakdown of acetylcholine.
An initial view of the potential impact of
chlorpyrifos on signaling targets in brain
development thus could resemble that of
nicotine (Figure 1), with promotion of
cholinergic signaling as the primary target.
However, chlorpyrifos also exhibits direct
cholinergic agonistlike properties, opening
and then desensitizing nicotinic cholin-
ergic receptor/ion channels (81); it inter-
acts with signaling intermediates such as
G-proteins and adenylyl cyclase (80,82,
83); and it may produce oxidative damage
to DNA (84,85).
If the primary effect ofchlorpyrifos on
the developing brain is a reflection of its
general mode oftoxicity as seen in mature
animals, namely cholinesterase inhibition,
then the net effects during development
should bear a strong resemblance to those
of nicotine, which also elicits cholinergic
hyperstimulation. When we administered
chlorpyrifos to neonatal rats (Figure 6), we
obtained acute inhibition ofDNA synthe-
sis (77). However, at 1 day of age, there
was no regional selectivity to the effect:
regions with low cholinergic innervation
(cerebellum) were affected just as much as
cholinergically enriched regions (brain-
stem, forebrain). Regional selectivity then
emerged by the end of the first postnatal
week, at which point cholinergic antago-
nists could block the effect. Thus, chlor-
pyrifos affects DNA synthesis by at least
two different types ofmechanisms, an ini-
tial, noncholinergic effect, and subse-
quently, actions mediated through
cholinergic activity. In support of the
unexpected finding of noncholinergic
contributions to effects on DNA synthe-
sis, we obtained the same inhibitory
actions when minute amounts of chlor-
pyrifos were injected directly into the
brain, bypassing hepatic activation to
chlorpyrifos oxon, the metabolite that
inhibits cholinesterase. The contributions
of noncholinergic mechanisms to the net
adverse effect on brain development are
readily demonstrable. With repeated
chlorpyrifos administration, we obtained
persistent inhibition of DNA synthesis
(86), leading to deficits in cell number
(87) and suppression of macromolecular
constituents (88). These effects were seen
at chlorpyrifos exposure levels that were
devoid of any overt toxicity and that
reduced cholinesterase activity by only
20% (80), a degree of inhibition insuffi-
cient to produce signs ofsystemic toxicity.
Some ofthe postulated, noncholinergic
effects ofchlorpyrifos involve cell signaling
intermediates common to multiple neu-
ronal and hormonal inputs, especially the
adenylyl cyclase transduction pathway
(82,83,89). Cyclic AMP is universally
involved in the control of cell replication
and differentiation in virtually all prokary-
otic and eukaryotic cells (90-94), so that
perturbation ofthis pathway during devel-
opmentwould be expected to have a signif-
icant impact on brain cell development.
When we examined the effects ofotherwise
subtoxic doses ofchlorpyrifos on adenylyl
cyclase activity in the developing brain
(80), we found profound effects on G-
protein-mediated signaling, including that
operating through neurotransmitter recep-
tors known to play neurotrophic roles in
cell replication/differentiation patterns
(Figure 7). Importantly, low doses of
chlorpyrifos administered early in develop-
ment, with minimal cholinesterase inhibi-
tion, had a much greater effect on adenylyl
cyclase activity than larger doses given
later in development, even though the lat-
ter treatment produced much greater inhi-
bition of cholinesterase. Again, this
indicates that noncholinergic mechanisms
play critical roles in the adverse effects of
chlorpyrifos on brain development. Thus,
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Figure 6. Inhibition of DNA synthesis after a single
dose of chlorpyrifos (771. Abbreviation: CPF, chlorpyri-
fos. Inhibition does not display regional selectivity until
the end of the first postnatal week, suggesting two
separate mechanisms: an initial, noncholinergic effect,
followed by a later-appearing, cholinergic effect. Data
represent means and standard errors obtained from
29-63 animals in each treatment group at each age.
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Figure 7. Effects of repeated chlorpyrifos administration on forebrain adenylyl cyclase activity (80). Abbreviations:
CPF, chlorpyrifos; PN, postnatal. Treatment with a low dose on postnatal days 1-4 produces a larger deficit than a
larger dose given later in development, despite the fact that the later treatment produces greater cholinesterase
inhibition. The effect on adenylyl cyclase emerges after a delay of several days after cessation of treatment, at a
time when cholinesterase activity has completely recovered to normal. Data represent means and standard errors
obtained from 11-12 animals in each treatment group at each age. ANOVA across age is shown within the panels
and asterisks (*) indicate individual values that differ significantly from the corresponding control.
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conversion of chlorpyrifos to its oxon
metabolite and the consequent inhibition
of cholinesterase may not be the essential
factors in determining neurobehavioral ter-
atology by this compound or potentially
for other insecticides as well.
Developmental Neurotoxicity
ofChlorpyrifos Modeled
in Vitro
A definitive demonstration that chlorpyrifos
exerts direct effects on neurodevelopment
requires control over the cellular environ-
ment, as provided by in vitro models. We
have used PC12 rat pheochromocytoma
cells, a cloned cell line that initially resem-
bles sympathetic neuronal precursor cells
but that differentiates to resemble sympa-
thetic neurons morphologically, physiologi-
cally, and biochemically (95,96). The onset
of differentiation is initiated by nerve
growth factor after which the cells develop
the appearance and function ofcholinergic
target neurons, including increased expres-
sion ofcholinergic receptors, choline acetyl-
transferase, and acetylcholinesterase (97,98).
Equally important, these cells lack cyto-
chrome P450 (99), the enzyme that con-
verts chlorpyrifos to its oxon, the metabolite
that inhibits cholinesterase. Thus, if the
actions ofchlorpyrifos seen for brain devel-
opment in vivo are paralleled by similar
actions on PC12 cells in vitro, the effects
cannot be secondary to cholinesterase
inhibition, the standard biomarker of
organophosphate-induced toxicity.
Using undifferentiated PC12 cells, we
obtained immediate (1 hr) inhibition of
DNA synthesis (Figure 8); effects on RNA
or protein synthesis were much less notable,
indicating a selectivity toward replicating
cells (100). The effect on DNAsynthesis in
undifferentiated PC12 cells could not be
blocked bycholinergic receptor antagonists,
confirming that chlorpyrifos itselfproduces
effect without a requirement for cholin-
esterase inhibition and its resultant cholin-
ergic hyperstimulation. When PC12 cells
were allowed to differentiate in the contin-
uous presence ofchlorpyrifos, the inhibi-
tion of DNA synthesis intensified and
persisted throughout the period of cell
development (Figure 9). As a consequence,
acquisition of new cells (DNA level) was
severely curtailed, or at the highest concen-
trations, completely arrested, replicating the
effects found for chlorpyrifos in vivo. In
contrast to the profound effects on DNA
synthesis and cell acquisition, neurite exten-
sion, as measured by the increase in mem-
brane surface area (protein/DNA ratio), was
inhibited only at high chlorpyrifos concen-
trations. These results confirm a targeted,
primary effect ofchlorpyrifos on cell repli-
cation, with other developmental abnor-
malities requiring higher exposure levels.
Just as was found for in vivo treatments, the
progression ofcell differentiation increases
the sensitivity to chlorpyrifos, representing
emergence ofthe cholinergic target pheno-
type; at that point, both direct and cholin-
ergically mediated effects become additive
(77), whereas only the direct effects can be
expressed in the undifferentiated state.
We have also carried out in vitro
studies in rat embryo cultures (67). Using
chlorpyrifos concentrations that showed
no evidence of growth reduction or dys-
morphogenesis, we found clear-cut abnor-
malities ofmitosis in the developing brain
at the neural tube stage. Embryos were
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Figure 8. Inhibition of DNA synthesis by chlorpyrifos in undifferentiated PC12 cells ( 100). Abbreviations: ATR,
atropine; CPF, chlorpyrifos; MEC, mecamylamine. Inhibition shows an immediate onset of action and is not medi-
ated by cholinergic hyperstimulation, as receptor blocking agents for muscarinic (atropine) or nicotinic (mecamy-
lamine) receptors do not prevent the effect. Data represent means and standard errors obtained from 6-17
determinations for each treatment and time point. ANOVA across all treatments and time points appear within
the panels and asterisks (*) denote individual values for which the treated groups differ from the corresponding
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incubated with chlorpyrifos for 48 hr
beginning on embryonic day 9.5 (Figure
10). Examination of the forebrain and
hindbrain regions revealed reduced and
altered mitotic figures with dispersion and
disorientation of the mitotic layer. In
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Figure 9. Effects of continuous exposure to chlorpyri-
fos on PC12 cells during differentiation (100).
Abbreviation: CPF, chlorpyrifos. The inhibition of DNA
synthesis is intensified and maintained throughout the
developmental period, leading to reduced or arrested
cell acquisition (DNA level). At the highest concentra-
tion, neurite extension (as measured by the protein/
DNA ratio) is also inhibited. Data represent means and
standard errors obtained from 20-36 determinations in
each group at each time point. ANOVA across all time
points and treatments appears within each panel and
asterisks (*) denote individual values that differ from
the corresponding control.
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Figure 10. Effects of chlorpyrifos on brain development in cultured rat embryos (67). Abbreviations: bv, blood vessel; CPF, chlorpyrifos; m, mitotic figure; n, inactive hete-
rochromatin. (A) Forebrain neuroepithelium in control embryos at embryonic day 11.5, showing a bipolar pseudostratified epithelium: apical and basal processes contain a
granular nucleus and inactive heterochromatin. Mitotic figure can be seen toward the internal limiting membrane. Mesenchyme around the germinal epithelium shows blood
vessel. (B) Neuroepithelium from an embryo exposed to chlorpyrifos (50 pg/mI). Note the extensive vacuolation of the cytoplasm of the epithelial cells (arrowheads). (C)
Forebrain neuroepithelium from a chlorpyrifos-exposed embryo showing extensive cell death (b) and extracellular bodies (arrowheads). A large cell (a) with multiple apoptotic
condensations is also visible. Scale bar =20 pm. For semi-quantitative measurements (table at bottom of figure), evaluations were made in numerous sections obtained from
four otherwise morphologically normal embryos in each treatment group. Over a much larger cohort (>40 embryos per treatment), there was no evidence of gross dysmorpho-
genesis orof changes in developmental landmarks aside from the disruption of cell development in the neuroepithelium.
addition, cytotoxicity was evidenced by
cytoplasmic vacuolation, enlargement of
intercellular spaces, and the presence of a
significant number of apoptotic figures.
Significant effects were found even at
concentrations as low as 0.5 pg/ml.
Our results with PC12 cells or rat
embryo cultures support the idea that
chlorpyrifos specifically targets brain devel-
opment. However, a major problem is how
to compare exposures in vitro with those
likely to be experienced with environmental
contamination. Certainly, the concentra-
tion and exposure period necessary to affect
brain cell development in vitro lie well
below those necessary for dysmorphogene-
sis, for chromosome damage (101) or for
general cytotoxicity (101,102). Although
scant information is available concerning
the actual levels ofchlorpyrifos achieved in
fetal brain, we have already demonstrated
that doses that cause only 20% cholin-
esterase inhibition nevertheless depress
mitosis in neonatal rat brain in vivo
(77,80,86), leading to deficiencies in cell
numbers (87). A preliminary report on
pregnant rats (103) found that a compara-
ble degree of cholinesterase inhibition,
which is well below the threshold for any
observable signs ofcholinergic hyperstimu-
lation, produces peak fetal brain concen-
trations of the major metabolite of
chlorpyrifos ofapproximately 0.25 pg/g,
which on a molar basis, corresponds to the
lowest concentration ofchlorpyrifos used
in our studies with embryos in vitro (67).
On a body weight basis, the doses ofchlor-
pyrifos needed for adult or developmental
toxicity in rats range up to tens to hundreds
ofmg/kg (78,79,104,105) and certainly no
lower than 2 mg/kg (77). Mitotic arrest in
vivo occurs with brain concentrations of 2
i'g/g (77), again well within the concen-
tration range needed for in vitro effects.
The likely acute exposure level for infants
after home application of chlorpyrifos is
also above this range: 350 pg/kg/day for a
2-week period, for a total of 5 mg/kg
(76). Although there are clear limitations
of extrapolation across species and bet-
ween cultures and intact systems, in vitro
evaluations nevertheless can point the way
to likely mechanisms and adverse out-
comes, and are likely to be within the
range ofrelevant exposure levels in vivo.
Conclusions and Future
Directions
Drugs or chemicals that target cholinergic
neurotransmission probably represent the
largest source of neurobehavioral teratoge-
nesis. Nicotine exposure involves one-
fourth of all pregnancies in the United
States, and exposure to insecticides that
target cholinesterase is ubiquitous. Estab-
lishing the underlying mechanisms, and
hence safety thresholds, for these compounds
must represent a major focus offuturework.
We have shown that nicotine damages the
developing brain at concentrations achieved
in moderate smokers or with nicotine
replacement therapies such as the transder-
mal patch. The sequelae ofmaternal smok-
ing are already well established (14) and
include high rates ofmiscarriage, fetal death,
intrauterine growth retardation, deaths in
the postnatal period, and behavioral and
learning disturbances. The finding that a
specific substance in tobacco (nicotine) is a
major contributor to adverse outcomes pro-
vides the first definitive proofthat tobacco is
a direct cause ofthese problems, not simply
a covariable with other components ofthe
smoking life style. In the case ofchlorpyri-
fos, our findings indicate that inhibition of
cholinesterase, the standard biomarker for
organophosphate toxicity, is inadequate to
explain the effects of this compound on
brain development. The uncovering ofalter-
native mechanisms indicates the need for
research on screening methods that empha-
size unique attributes ofdeveloping systems
such as DNA synthesis, cell acquisition,
apoptosis, and cytoarchitectural modeling of
specific brain regions. In vitro systems such
as neural cell lines or embryo cultures can
play key roles in elaborating these mecha-
nisms and in establishing new safety
thresholds for insecticide exposure during
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development. Finally, it should not be over-
looked that unlike standard teratogens,
agents that target specific cell populations
in the nervous system rather than general
organogenesis, can be expected to have
adverse effects that extend to the final stages
of development: childhood and adoles-
cence. In the future, we will need to acquire
new ways ofevaluating potential postnatal
effects ofenvironmental contaminants.
REFERENCES AND NOTES
1. Buznikov GA, Chudakova IV, Zvedina ND. The
role of neurohumors in early embryogenesis. 1:
Serotonin content of developing embryos of sea
urchin and loach. J Embryol Exp Morphol
12:563-573(1964).
2. Buznikov GA, Kost AN, Berdysheva LV. The role
of neurohumours in early embryogenesis. 3:
Pharmacological analysis of the role of neuro-
humours in cleavage divisions. J Embryol Exp
Morphol 23:549-569 (1970).
3. LauderJM. Roles forneurotransmitters in devel-
opment: possible interaction with drugs during
the fetal and neonatal periods. In: Prevention of
Physical and Mental Congenital Defects (Marois
M, ed). NewYork:Alan R. Liss, 1985;375-380.
4. Whitaker-Azmitia PM. Role of serotonin and
other neurotransmitter receptors in brain devel-
opment: basis for developmental pharmacol-
ogy. Pharmacol Rev43:553-561 (1991).
5. Yanai J. Neurobehavioral Teratology.
Amsterdam:Elsevier, 1984.
6. Hohmann CF, Wilson L, Coyle JT. Efferent and
afferent connections of mouse sensory-motor
cortex following cholinergic deafferentation at
birth. Cereb Cortex 1:1158-172 (1991).
7. Bachman ES, Berger-Sweeney J, Coyle JT,
Hohmann CF. Developmental regulation of
adult cortical morphology and behavior: an ani-
mal model for mental retardation. Int J Dev
Neurosci 12:239-253 (1994).
8. Hohmann CF, Brooks AR, Coyle JT. Neonatal
lesions of the basal forebrain cholinergic neu-
rons result in abnormal cortical development.
Dev Brain Res 42:253-264 (1988).
9. Navarro HA, Seidler FJ, Eylers JP, Baker FE,
Dobbins SS, Lappi SE, Slotkin TA. Effects of
prenatal nicotine exposure on development of
central and peripheral cholinergic neurotrans-
mitter systems. Evidence for cholinergic trophic
influences in developing brain. J Pharmacol Exp
Ther251:894-900 (1989).
10. McFarland BJ, Seidler FJ, Slotkin TA. Inhibition
of DNA synthesis in neonatal rat brain regions
caused by acute nicotine administration. Dev
Brain Res 58:223-229 (1991).
11. Bell JM, Lundberg PK. Effects of a commercial
soy lecithin preparation on development of sen-
sorimotor behavior and brain biochemistry in
the rat. Dev Psychobiol 18:59-66 (1985).
12. Bell JM, Whitmore WL, Barnes G, Seidler FJ,
Slotkin TA. Perinatal dietary exposure to soy
lecithin: altered sensitivity to central choliner-
gic stimulation. Int J Dev Neurosci 4:497-501
(1986).
13. Bardy AH, Seppala T, Lilisunde P, Kataja JM,
Koskela P, Pikkarainen J, Hiilesmaa VK.
Objectively measured tobacco exposure during
pregnancy: neonatal effects and relation to
maternal smoking. Br J Obstet Gynaecol
100:721-726 (1993).
14. DiFranza JR, Lew RA. Effect of maternal ciga-
rette smoking on pregnancy complications and
Sudden Infant Death Syndrome. J Fam Pract
40:385-394 (1995).
15. Butler,NR, Goldstein H. Smoking in pregnancy
and subsequent child development. Br Med J
4:573-574 (1973).
16. Naeye RL. Effects of maternal cigarette smok-
ing on the fetus and placenta. Br J Obstet
Gynaecol 85:732-737 (1978).
17. Naeye Rl, Peters EC. Mental development of
children whose mothers smoked during preg-
nancy. Obstet Gynecol 64:601-607 (1984).
18. Naeye RL. Cognitive and behavioral abnormali-
ties in children whose mothers smoked ciga-
rettes during pregnancy. J Dev Behav Pediatr
13:425-8 (1992).
19. Dunn HG, McBurney AK. Cigarette smoking
and the fetus and child. Pediatrics 60:772
(1977).
20. Bell GL, Lau K. Perinatal and neonatal issues of
substance abuse. Pediatr Clin North Am
42:261-281 (1995).
21. Martin JC, Becker RF. The effects of nicotine
administration in utero upon activity in the rat.
Psychon Sci 19:59-60 (1970).
22. Martin JC, Becker RF. The effects of maternal
nicotine absorption or hypoxic episodes upon
appetitive behavior of rat offspring. Dev
Psychobiol 4:133-147 (1971).
23. Nasrat HA, AI-Hachim GM, Mahmood FA.
Perinatal effects of nicotine. Biol Neonate
49:8-14(1986).
24. Slotkin TA, Greer N, Faust J, Cho H, Seidler FJ.
Effects of maternal nicotine injections on brain
development in the rat: ornithine decarboxy-
lase activity, nucleic acids and proteins in dis-
crete brain regions. Brain Res Bull 17:41-50
(1986).
25. Slotkin TA, Cho H, Whitmore WL. Effects of
prenatal nicotine exposure on neuronal devel-
opment: selective actions on central and
peripheral catecholaminergic pathways. Brain
Res Bull 18:601-611 (1987).
26. Slotkin TA, Orband-Miller L, Queen KL.
Development of [3H]nicotine binding sites in
brain regions of rats exposed to nicotine prena-
tally via maternal injections or infusions. J
Pharmacol Exp Ther 242:232-237 (1987).
27. Slotkin TA, Cowdery TS, Orband L, Pachman S,
Whitmore Wl. Effects of neonatal hypoxia on
brain development in the rat: immediate and
long-term biochemical alterations in discrete
regions. Brain Res 374:63-74 (1986).
28. Seidler FJ, Slotkin TA. Effects of acute hypoxia
on neonatal rat brain: regionally selective,
long-term alterations in catecholamine levels
and turnover. Brain Res Bull 24:157-161
(1990).
29. Carlos RQ, Seidler FJ, Lappi SE, Slotkin TA.
Fetal dexamethasone exposure affects basal
ornithine decarboxylase activity in developing
rat brain regions and alters acute responses to
hypoxia and maternal separation. Biol Neonate
59:69-77 (1991).
30. Jonsson G, Hallman H. Effects of neonatal
nicotine administration on the postnatal devel-
opment of central noradrenaline neurons. Acta
Physiol Scand Suppl 479:25-26 (1980).
31. Slotkin TA. Prenatal exposure to nicotine: What
can we learn from animal models? In: Maternal
Substance Abuse and the Developing Nervous
System (Zagon IS, Slotkin TA, eds). San Diego:
Academic Press, 1992;97-124.
32. Slotkin TA, Orband-Miller L, Queen KL,
Whitmor WL, Seidler FJ. Effects of prenatal
nicotine exposure on biochemical development
of rat brain regions: maternal drug infusions via
osmotic minipumps. J Pharmacol Exp Ther 240:
602-611 (1987).
33. Navarro HA, Seidler FJ, Whitmore WL, Slotkin
TA. Prenatal exposure to nicotine via maternal
infusions: effects on development of cate-
cholamine systems. J Pharmacol Exp Ther
244:940-944 (1988).
34. Navarro HA, Seidler FJ, Schwart RD, BakerFE,
Dobbins SS, Slotkin TA. Prenatal exposure to
nicotine impairs nervous system development
at a dose which does not affect viability or
growth. Brain Res Bull 23:187-192 (1989).
35. Murrin LC, Ferrer JR, Wanyun Z, Haley NJ.
Nicotine administration to rats: methodological
considerations. Life Sci 40:1699-1708 (1987).
36. Lichtensteiger W, Ribary U, Schlumpf M,
Odermatt B, Widmer HR. Prenatal adverse
effects of nicotine on the developing brain.
Prog Brain Res 73:137-157 (1988).
37. Barnes CD, Eltherington LG. Drug Dosage in
Laboratory Animals: A Handbook. Revised ed.
Berkeley, CA:University of California Press, 1973.
38. Slotkin TA, McCook EC, Seidler FJ. Cryptic
brain cell injury caused by fetal nicotine expo-
sure is associated with persistent elevations of
c-fos protooncogene expression. Brain Res
750:180-188 (1997).
39. Slotkin TA. Fetal nicotine or cocaine exposure:
which one is worse? J Pharmacol Exp Ther
285:931-945 (1998).
40. Roy TS, Andrews JE, Seidler FJ, Slotkin TA.
Nicotine evokes cell death in embryonic rat
brain during neurulation. J Pharmacol Exp Ther
(in press).
41. Owman C, Fuxe K, Janson AM, Kahrstrom J.
Chronic nicotine treatment eliminates asymme-
try in striatal glucose utilization following uni-
lateral transection of the mesostriatal
dopamine pathway in rats. Neurosci Lett
102:279-283 (1989).
42. Janson AM, Fuxe K, Agnati LF, Kitayama I,
Harfstrand A, Andersson K, Goldstein M.
Chronic nicotine treatment counteracts the dis-
appearance of tyrosine-hydroxylase-immunore-
active nerve cell bodies, dendrites and
terminals in the mesostriatal dopamine system
of the male rat after partial hemitransection.
Brain Res 455:332-345)1988).
43. Yamashita H, Nakamura S. Nicotine rescues
PC12 cells from death induced by nerve growth
factor deprivation. Neurosci Lett 213:145-147
(1996).
44. Kaneko S, Maeda T, Kume T, Kochiyama H,
Akaike A, Shimohama S, Kimura J. Nicotine
protects cultured cortical neurons against glu-
tamate-induced cytotoxicity via a7-neuronal
receptors and neuronal CNS receptors. Brain
Res 765:135-140 (1997).
78 Environmental Health Perspectives * Vol 107, Supplement * February 1999CHOUNOTOXICANTS: NICOTINE AND CHLORPYRIFOS
45. Curran T, Abate C, Cohen DR, Macgregor PF,
Rauscher FJ, Sonnenberg JL, Connor JA,
Morgan, JI. Inducible proto-oncogene transcrip-
tion factors: third messengers in the brain?
Cold Spring Harbor Symp Quant Biol 55:225-
234(1990).
46. Curran T, Morgan JI. Fos: an immediate-early
transcription factor in neurons. J Neurobiol
26:403-412 (1995).
47. Scotting, PJ, Rex, M. Transcription factors in
early development of the central nervous sys-
tem. Neuropathol AppI Neurobiol 22:469-481
(1996).
48. Blishchenko EY, Mirkina II, Mernenko OA,
Yatskin ON, Satpaev DK, Strizhkov BN, Karelin
AA. Cytotoxic activity of acetylcholine receptor
ligands. Biochem Mol Biol Int 42:739-747
(1997).
49. Zahalka EA, Seidler FJ, Lappi SE, McCook EC,
Yanai J, Slotkin TA. Deficits in development of
central cholinergic pathways caused by fetal
nicotine exposure: differential effects on
choline acetyltransferase activity and [3H]hemi-
cholinium-3 binding. Neurotoxicol Teratol
14:375-382 (1992).
50. Lichtensteiger W, Schlumpf M. Prenatal nico-
tine affects fetal testosterone and sexual
dimorphism of saccharin preference. Pharmacol
Biochem Behav23:439-444 (1985).
51. Ribary U, Lichtensteiger W. Effects of acute
and chronic prenatal nicotine treatment on cen-
tral catecholamine systems of male and female
ratfetuses and offspring. J Pharmacol Exp Ther
248:786-792 (1989).
52. Seidler FJ, Levin ED, Lappi SE, Slotkin TA. Fetal
nicotine exposure ablates the ability of postna-
tal nicotine challenge to release norepinephrine
from rat brain regions. Dev Brain Res 69:288-
291 (1992).
53. SlotkinTA, Navarro HA, McCook EC, Seidler FJ.
Fetal nicotine exposure produces postnatal up-
regulation of adenylate cyclase activity in
peripheral tissues. Life Sci 47:1561-1567
(1990).
54. Slotkin TA, McCook EC, Lappi SE, Seidler FJ.
Altered development of basal and forskolin-
stimulated adenylate cyclase activity in brain
regions of rats exposed to nicotine prenatally.
DevBrain Res68:233-239(1992).
55. Zahalka EA, Seidler FJ, Yanai J, Slotkin TA.
Fetal nicotine exposure alters ontogeny of M1-
receptors and their link to G-proteins.
Neurotoxicol Teratol 15:107-115(1993).
56. Navarro HA, Mills E, Seidler FJ, Baker FE, Lappi
SE, Tayyeb Ml, Spencer JR, Slotkin TA.
Prenatal nicotine exposure impairs 0-adrener-
gic function: persistent chronotropic subsensi-
tivity despite recovery from deficits in receptor
binding. Brain Res Bull 25:233-237 (1990).
57. Navarro HA, Slotkin TA, Tayyeb Ml, Lappi SE,
Seidler FJ. Effects offetal nicotine exposure on
development of adrenergic receptor binding in
rat brain regions: selective changes in al-
receptors. Res Commun Subst Abuse 11:95-
103(1990).
58. Dodge PR, Prensky AL, Feigin RD. Nutrition and
the Developing Nervous System. St. Louis:C.V.
Mosby, 1975.
59. de Grauw TJ, Myers RE, Scott WJ. Fetal
growth retardation in rats from different levels
of hypoxia. Biol Neonate 49:85-89(1986).
60. Bell JM, Whitmore WL, Queen KL, Orband-
Miller L, Slotkin TA. Biochemical determinants
of growth sparing during neonatal nutritional
deprivation or enhancement: ornithine decar-
boxylase, polyamines, and macromolecules in
brain regions and heart. Pediatr Res
22:599-604(1987).
61. Martino-Barrows AM, Kellar KJ. [3H]Acety-
choline and [3H](-)nicotine label the same
recognition site in rat brain. Mol Pharmacol
31:169-174 (1987).
62. Cairns NJ, Wonnacott S. [3H](-)Nicotine binding
sites in fetal human brain. Brain Res 475:1-7
(1988).
63. Hagino N, Lee JW. Effect of maternal nicotine
on the development of sites for [3H-nicotine
binding in the fetal brain. Int. J Dev Neurosci
3:567-571 (1985).
64. Larsson C, Nordberg A, Falkeborn Y, Lundberg
R-A. Regional PHIacetylcholine and [3Hlnicotine
binding in developing mouse brain. Int J Dev
Neurosci 3:667-671 (1985).
65. Lichtensteiger W, Schlumpf M, Ribary U.
Modifications pharmacologiques de I'onto-
genese neuroendocrine. Ann Endocrinol
48:393-399 (1987).
66. Smith WT, Seidler FJ, Slotkin TA. Acute stimu-
lation of ornithine decarboxylase in neonatal
rat brain regions by nicotine: a receptor-medi-
ated process? Dev Brain Res 63:85-93 (1991).
67. Roy TS, Andrews JE, Seidler FJ, Slotkin TA.
Chlorpyrifos elicits mitotic abnormalities and
apoptosis in neuroepithelium of cultured rat
embryos. Teratology 58:62-68(1998).
68. Cutler AR, Wilkerson AE, Gingras JL, Levin ED.
Prenatal cocaine and/or nicotine exposure in
rats: preliminary findings on long-term cognitive
outcome and genital development at birth.
Neurotoxicol Teratol 18:635-643(1996).
69. Levin ED, Wilkerson A, Jones JP, Christopher
NC, Briggs SJ. Prenatal nicotine effects on
memory in rats: pharmacological and behav-
ioral challenges. Dev Brain Res 97:207-215
(1996).
70. Levin ED, Briggs SJ, Christopher NC, Rose JE.
Prenatal nicotine exposure and cognitive per-
formance in rats. Neurotoxicol Teratol
15:251-260 (1993).
71. Pugh PC, Berg DK. Neuronal acetylcholine
receptors that bind ax-garotoxin mediate neurite
retraction in a calcium-dependent manner. J
Neurosci 14:889-896(1994).
72. Hellstrom-Lindahl E, Gorbounova 0, Seiger A,
Mousavi M, Nordberg A. Regional distribution
of nicotinic receptors during prenatal develop-
ment of human brain and spinal cord. Dev Brain
Res 108:147-160 (1998).
73. Shacka JJ, Robinson SE. Postnatal develop-
mental regulation of neuronal nicotinic receptor
subunit a7 and multiple a4 and 02 mRNA
species in the rat. Dev Brain Res 109:67-75
(1998).
74. Richardson RJ, Moore TB, Kayyali US, Randall
JC. Chlorpyrifos: assessment of potential for
delayed neurotoxicity by repeated dosing in
adult hens with monitoring of brain acetyl-
cholinesterase, brain and lymphocyte neurotoxic
esterase and plasma butyrylcholinesterase
activities. FundamAppI Toxicol 21:89-96(1993).
75. Fenske RA, Black KG, Elkner KP, Lee C, Methner
MM, Soto R. Potential exposure and health
risks of infants following indoor residential pes-
ticide applications. Am J Public Health
80:689-693 (1990).
76. Gurunathan S, Robson M, Freeman N, Buckley
B, Roy A, Meyer R, Bukowski J, Lioy PJ. Accu-
mulation of chlorpyrifos on residential surfaces
and toys accessible to children. Environ Health
Perspect 106:9-16 (1998).
77. Whitney KD, Seidler FJ, Slotkin TA.
Developmental neurotoxicity of chlorpyrifos:
cellular mechanisms. Toxicol AppI Pharmacol
134:53-62 (1995).
78. Pope CN, Chakraborti TK, Chapman ML, Farrar
JD, Arthun D. Comparison of in vivo
cholinesterase inhibition in neonatal and adult
rats by three organophosphorothioate insecti-
cides. Toxicology 68:51-61 (1991).
79. Pope CN, Chakraborti TK. Dose-related inhibi-
tion of brain and plasma cholinesterase in
neonatal and adult rats following sublethal
organophosphate exposures. Toxicology
73:35-43 (1992).
80. Song X, Seidler FJ, Saleh JL, Zhang J, Padilla
S, Slotkin TA. Cellular mechanisms for develop-
mental toxicity of chlorpyrifos: targeting the
adenylyl cyclase signaling cascade. Toxicol
AppI Pharmacol 145:158-174 (1997).
81. Katz EJ, Cortes VI, Eldefrawi ME, Eldefrawi AT.
Chlorpyrifos, parathion, and their oxons bind to
and desensitize a nicotinic acetylcholine recep-
tor: relevance to their toxicities. Toxicol AppI
Pharmacol 146:227-236 (1997).
82. Huff RA, Abou-Donia MB. In vitro effect of
chlorpyrifos oxon on muscarinic receptors and
adenylate cyclase. Neurotoxicology 16:281-290
(1995).
83. Huff RA, Corcoran JJ, Anderson JK, Abou-
Donia MB. Chlorpyrifos oxon binds directly to
muscarinic receptors and inhibits cAMP accu-
mulation in rat striatum. J Pharmacol Exp Ther
269:329-335 (1994).
84. Bagchi D, Bagchi M, Hassoun EA, Stohs SJ. In
vitro and in vivogeneration of reactive oxygen
species, DNA damage and lactate dehydroge-
nase leakage by selected pesticides. Toxicology
104:129-140 (1995).
85. Bagchi D, Bhattacharya G, Stohs SJ. In vitro
and in vivo induction of heat shock (stress) pro-
tein (Hsp) gene expression by selected pesti-
cides. Toxicology 112:57-68(1996).
86. Dam K, Seidler FJ, Slotkin TA. Developmental
neurotoxicity of chlorpyrifos: delayed targeting
of DNA synthesis after repeated administra-
tion. Dev Brain Res 108:39-45(1998).
87. Campbell CG, Seidler FJ, Slotkin TA.
Chlorpyrifos interferes with cell development in
rat brain regions. Brain Res Bull 43:179-189
(1997).
88. Johnson DE, Seidler FJ, Slotkin TA. Early bio-
chemical detection of delayed neurotoxicity
resulting from developmental exposure to
chlorpyrifos. Brain Res Bull 45:143-147 (1998).
89. Ward TR, Mundy WR. Organophosphorus com-
pounds preferentially affect second messenger
systems coupled to M2/M4 receptors in rat
frontal cortex. Brain Res Bull 39:49-55(1996).
90. Claycomb WC. Biochemical aspects of cardiac
muscle differentiation. J Biol Chem 251:
6082-6089(1976).
91. HultgArdh-Nilsson A, Querol-Ferrer V, Jonzon B,
Krondahl, U, Nilsson J. Cyclic AMP, early
Environmental Health Perspectives * Vol 107, Supplement 1 * February 1999 79TA SLOTKIN
response gene expression, and DNA synthesis
in rat smooth muscle cells. Exp Cell Res
214:297-302 (1994).
92. Van Wijk R, Wicks WD, Bevers MM, Van Rijn J.
Rapid arrest of DNA synthesis by N6,02'-dibu-
tyryl cyclic adenosine 3',5'-monophosphate in
cultured hepatoma cells. Cancer Res 33:
1331-1338 (1973).
93. Bhat NR, Shanker G, Pieringer RA. Cell prolifer-
ation in growing cultures of dissociated embry-
onic mouse brain: macromolecule and ornithine
decarboxylase synthesis and regulation by hor-
mones and drugs. J Neurosci Res 10:221-230
(1983).
94. Guidotti A. Adenosine 3',5'-monophosphate
concentrations and isoproterenol-induced syn-
thesis ofdeoxyribonucleic acid in mouse parotid
gland. Mol Pharmacol 8:521-530(1972).
95. Tischler AS, Greene LA. Nerve growth factor-
induced process formation by cultured rat
pheochromocytoma cells. Nature 258:341-342
(1975).
96. Greene LA, Tischler AS. Establishment of a
noradrenergic clonal line of rat adrenal
pheochromocytoma cells which respond to
nerve growth factor. Proc Nati Acad Sci 73:
2424-2428(1976).
97. Greene LA, Rukenstein A. Regulation of acetyl-
cholinesterase activity by nerve growth factor:
role of transcription and dissociation from
effects on proliferation and neurite outgrowth.
J Biol Chem 256:6363-6367 (1981).
98. Berse B, Blusztajn JK. Modulation of choliner-
gic locus expression by glucocorticoids and
retinoic acid is cell-type specific. FEBS Lett
410:175-179(1997).
99. Mapoles J, Berthou F, Alexander A, Simon F,
Menez JF. Mammalian PC-12 cell genetically
engineered for human cytochrome P450 2E1
expression. J Biochem 214:735-745 (1993).
100. Song X, Violin JD, Seidler FJ, Slotkin TA.
Modeling the developmental neurotoxicity of
chlorpyrifos in vitro: macromolecule synthesis
in PC12 cells. Toxicol AppI Pharmacol 151:
182-191 (1998).
101. Muscarella DE, Keown JF, Bloom SE. Evaluation
of the genotoxic and embryotoxic potential of
chlorpyrifos and its metabolites in vivo and in
vitro. Environ Mutagen 6:13-23 (1984).
102. Cosenza ME, Bidanet J. Effects of chlorpyrifos
on neuronal development in rat embryo mid-
brain micromass cultures. Vet Human Toxicol
37:118-121 (1995).
103. Hunter DL, Lassiter TL, Chanda SM, Barone S,
Padilla S. Pharmacokinetics of chlorpyrifos and
its metabolites in maternal and fetal brain and
liver tissue following gestational exposure.
Toxicologist 42:157-158 (1998).
104. Chakraborti TK, Farrar JD, Pope CN.
Comparative neurochemical and neurobehav-
ioral effects of repeated chlorpyrifos exposures
in young and adult rats. Pharmacol Biochem
Behav46:219-224 (1993).
105. Bushnell PJ, Pope CN, Padilla S. Behavioral and
neurochemical effects of acute chlorpyrifos in
rats: tolerance to prolonged inhibition of
cholinesterase. J Pharmacol Exp Ther
266:1007-1017 (1993).
106. Tolson CM, Seidler FJ, McCook EC, Slotkin TA.
Does concurrent orpriornicotine exposure inter-
act with neonatal hypoxia to produce cardiac
cell damage? Teratology52:299-305 (1995).
80 Environmental Health Perspectives * Vol 107, Supplement 1 * February 1999